NEW YORK, Aug. 25, 2016 /PRNewswire/ -- This Kalorama
Information report, The Worldwide Market for In Vitro Diagnostic
Tests, has been updated for two decades in ten editions, keeping
readers informed about developments in all areas of IVD, around the
world, in one volume. The 1,600-page report provides market size
estimates and projections for the entirety of the clinical
diagnostics testing market. It also tracks hundreds of competitors,
notes significant partnerships, distribution deals and acquisitions
and defines the market share situation for the IVD market and
competitive analysis for many segments.
Market Size and Forecast for All IVD Market Segments
Published every two years, this report estimates current market
size and forecasted market size to 2021 for defined segments of the
IVD market and various sub-segments, including:
Molecular Assays (Infectious Disease, Blood Screening, Inherited
Diseases, Oncology, Pharmacodiagnostics, Tissue Typing,
Prenatal)
Clinical Chemistry and "Core Lab" Markets (including sub segment
revenues for General Chemistries, Workstations, Analyzers Blood
Gases, Urinalysis, Critical Care)
Point-of-Care Testing (POC), (Professional and Self-Testing,
Glucose Testing, Pregnancy Tests, drugs of abuse, HIV, H. pylori,
Other, OTC/Self Total, Professional POC, Cardiac Markers, Drugs of
Abuse, HbA1c, Pregnancy, Other)
Microbiology and Virology by Test Type (Immunoassays, ID/AST,
Infectious Diseases - DNA; ID/AST: Panels and Reagents, automated;
Panels and Reagents, manual; Blood Culture; Chromogenic Media;
Rapid Micro; Supplies)
Blood Banking (Grouping, Immunoassay Screens, NAT Screens)
Tissue-Based Testing - Histology and Cytology (Pap, ISH, IHC,
HPV)
Infectious Disease Immunoassay Testing (Hepatitis, HIV, STDs,
TORCH, Respiratory, Sepsis, Parasitology, Mycology, Others)
Hematology
Molecular Tests in Infectious Diseases (HAI, HIV, Hepatitis,
GC/Chlamydia, Respiratory, Organism ID, Mycobacteria, TB,
Others
Non-Infectious Disease Immunoassay Sales by Analyte Type (Cardiac
markers, Tumor markers, Diabetes/HbA1c, Autoimmune, Allergy,
Thyroid, Proteins, Anemia, Fertility, Therapeutic drugs, Tox/Drugs
of abuse, Vitamin D)
Coagulation Tests (Lab-Based, POC, Genetic Markers)
Sequencing and Flow Cytometry
No other report provides similar understanding of the world
diagnostics market. For each of the listed segments, 2016 market
size, 2021 projection and compound annual growth rate is provided,
as well as significant companies in the market and product
innovations. The market data is put into a context with real-world
industry and medical practice trends. Shara
Rosen (MBA, RT), has authored ten editions of this superior
work intended to provide IVD market coverage in a world
perspective. The report has been called "The Bible of the IVD
Industry" by customers, which include top IVD firms. Using Kalorama
Information's report ensures that your firm will have the
perspective and data of others in the industry and those that track
the industry and invest in it.
Regional and Country IVD Markets Defined
In vitro diagnostics is a global market and the report reflects the
global scope. Companies sell globally and think globally. Trends in
one part of the world affect product decisions and company
financial performance in others. Thus, this is a global report and
the following regional and country overall IVD markets are
included:
US
Europe
Germany
UK
France
Spain
Italy
Russia
Netherlands
Turkey
Poland
Canada
China
Japan
Saudi Arabia
Brazil
Latin America
Eastern Europe
Emerging Markets
Rest of World
The Worldwide Market for In Vitro Diagnostic Tests is a testament
to the Kalorama methodology. It is the result of months of
painstaking work by an experienced IVD industry analyst, who has
tracked hundreds of companies for developments, trends and
financial results. This research is compiled along with the
opinion, observations and insights of industry experts to produce
an unparalleled vision of the industry as it is in 2016.
Superior Company Profiling
The report concentrates over a thousand pages on detailed and
tiered profiles of companies in the in vitro diagnostics markets.
The experience that Kalorama Information has in this market is
evident in its tiering and segmentation of companies.
Top Tier Companies: These are the dominant companies in IVD. For
each company, extensive, discussion of recent financial performance
is provided. Their main products are detailed and any significant
company strategies, partnerships and acquisitions are
considered:
Abbott Diagnostics
Alere Inc
Beckman Coulter, Inc. / Danaher
Becton, Dickinson and Company (BD)
bioMérieux Inc.
Bio-Rad Laboratories
Hologic
Instrumentation Laboratory (IL)
Ortho Clinical Diagnostics (OCD)
QIAGEN N.V
Roche Diagnostics
Siemens Healthineers
Sysmex Corporation
Thermo FisherScientific
Werfen Group S.A.
Next Tier IVD Companies: growth-oriented companies that have
significant presence in one or several areas are profiled and their
new products and strategies discussed in the report. Among
these:
Affymetrix Inc.
Cepheid
ERBA Diagnostics, Inc
DiaSorin S.p.A
Illumina
Luminex Corporation
Menarini Diagnostics.
Mindray Medical International Limited
Myriad Genetics
Perkin Elmer, Inc. (PE)
Quidel Corporation
Randox Laboratories Ltd
Royal Philips
TOSOH Corporation
Trinity Biotech
Wako Pure Chemical Industries
Specialist Companies: While these companies focus on one segment of
the IVD market, they can often be dominant in the They are
important to watch because they can often develop products in new
areas of testing and move categories.
Molecular Specialists
Blood Banking Specialists
Point of Care Specialists
Prenatal Test Service Providers
Quality Control and Pretreatment Specialists
CoagulationSpecialists
Histology and Cytology Specialists
Microbiology Specialists
IT SolutionsCompanies
CTC and Liquid Biopsy Specialists
Deep Understanding of IVD Market Trends
Published continuously for two decades, the report reflects the
experience Kalorama has in watching events in IVD and the emergence
and reemergence of industry, technological and clinical trends. For
instance:
The revolution in bioinformatics is allowing clinical and
traditional medical engineering to blend with components derived
from the telecommunications, information and computer sciences
industries. This opens new niche markets for POC test devices,
which will have a positive impact on diagnostic testing.
Getting information to care givers and patients is now not an added
plus, it is a prerequisite of all lab operations. Thus the next 3-5
years will see an intensification of the healthcare industry's
emphasis on informatics, wireless communications, data networking
and cost/effective healthcare delivery.
In the area of test economics, outcomes based disease management
establishes guidelines and directives for patient care. This is
having a significant effect on the use of new tests, which have to
prove their added value to patient care. It also affects how many
and which tests are recommended and thus reimbursed for a specific
disease group.
None of the above would be happening without significant forces in
the market driving them. This updated report presents the trends,
technologies, customer needs and major suppliers with an eye on how
they are shaping the IVD industry, including the following
trends:
Top 20 Companies and Niche Players 2012-2016
Acquisitions in the IVD Market
NGS, LC-MS and Other Novel Testing
Lab Market Segmentation (Hospital, Independent, POLs)
Emerging Markets
Digital Technology, IT and Big Data
Gene Editing
Wearables
Europe and Austerity
Status of LDTs
State of Biomarker Discovery
Test Services Trend
Distribution Agreements
Role of Sequencing
Non-Blood Sampling
LDT Regulatory Picture
New Product Launches
Near-Patient Testing
DTC Testing
New Testing Venues
The Most Comprehensive Picture of Today's IVD Industry
In addition to providing superior business planning tools, the
following are among the many topics that the report tackles:
20 Years of IVD: A summary of the IVD industry from 1995 to the
present. Amazingly a lot has changed – new tests and technologies
have come to market but the very same major companies generate
about 90% of product sales.
Demographics: A number of world events bode well for the future of
medical devices: an aging worldwide population and demand for new
hospitals in developing countries.Increasing numbers of people
between the ages of 45 and 75 years in the industrialized world
consume more healthcare services such as heart and cancer tests.
IVD companies are casting their nets in developing countries, where
rising incomes and standards of living have sparked a new health
consciousness and growing demands for quality medical care. The
next five to ten years or so will see moderate and gradual change
in IVD product markets.
Changing Core Lab: Not 10-15 years ago most microbiology and
anatomic pathology labs were tucked away somewhere in the basement.
The major test areas similarly were separated by impenetrable
walls.
Those days aregone: imagine a centralized hospital lab where
clinical chemistry, immunoassays, hematology, coagulation,
urinalysis, some microbiology, some cytology tests are all
performed in one room and often on instrumentation that are linked
by an automated track line and all in the same room. More
importantly by a lab information system that consolidates test
results to an electronic patient record.
Emerging Markets: High growth countries, primarily Saudi Arabia, Brazil, China
and India experience market growth
of double digits. This is fueled by privatization and health
insurance initiatives by governments and employers. However this
growth has a negligible effect to compensate for the lack of
significant growth in major markets of Europe, Japan
and the U.S.
IVD-Focused Government Initiatives: New healthcare disease
screening and health insurance initiatives proposed by the new
U.S.administration under the guidance of President Barack Obama further bolster the use of IVDs,
but continued economic difficulties has U.S. citizens forgo
elective procedures because the co-payments may be somewhat
unaffordable.
Automation: There is also a lack of trained lab technologists, so
there is a decreasing availability of human resources needed to run
the more complex new set of molecular and histological tests and
immunoassays.
Therefore there has been a proliferation of test and lab automation
tools launched that remove precious human resources from mundane
pre-analytical and sample-tracking tasks to make time for more
sophisticated ones. This phenomenon was once thought to be the
purview of core lab biochemistry and immunoassays but automation is
becoming a common feature hematology, blood banking,microbiology,
and histology. Demand for healthcare and thus diagnostic tests in
all the major markets is driven by aging populations and increased
incidence of conditions such as: cancer, diabetes,cardiovascular
disease, arthritis and obesity.In light of the demand for these
tests, they have been reformulated for automated analyzers where
the cost per test is traditionally low.
New Sampling: No more blood sampling: be prepared for an IVD world
of breath tests for conditions that includes respiratory
infections,gastrointestinal disorders, cancer and even chronic
diseases. Wearable patch sensors have been commercialized for
glucose and vital signs monitoring; more and more applications are
in development.
Sequencing Enters the Clinic: In the 21st century, understanding a
patient's personal genomic profile equips physicians with valuable
information to better diagnose, predict, treat and prevent disease.
Personalized medicine using genomic information improves patient
outcomes and reduces healthcare costs and adverse drug reactions.
The NGS data analysis market includes the market by product
(software and services) and by applications such as whole genome
sequencing, exome sequencing, targeted re-sequencing, de novo
sequencing, RNA-Seq, ChIP-Seq and Methyl-Seq. As experience with
sequencing intensifies, researchers are beginning to discover some
of the ways in which the technology can be used. It is generally
anticipated that whole genome sequencing is most appropriate for
broad research looking for linkages between gene mutations and
disease development.
These and many more topics are covered in The World Market for In
Vitro Diagnostic Tests, 10th Edition. We publish other specific
reports in molecular diagnostics, U.S. IVD, companion diagnostics
and next generation sequencing and many others. Our entire library
of reports are available via our Knowledge Center service at
considerable savings and convenience for your company.
Read the full report:
http://www.reportlinker.com/p04090323-summary/view-report.html
About Reportlinker
ReportLinker is an award-winning market research solution.
Reportlinker finds and organizes the latest industry data so you
get all the market research you need - instantly, in one place.
http://www.reportlinker.com
__________________________
Contact Clare: clare@reportlinker.com
US: (339)-368-6001
Intl: +1 339-368-6001
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/the-worldwide-market-for-in-vitro-diagnostic-tests-10th-edition-300318512.html
SOURCE Reportlinker